AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11818767
Drug: Clonidine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (10 microg x kg(‐1) administered over 5 min + 5 microg x kg(‐1) x h(‐1) intravenous) given after mu-opioid receptor blockade
Trial: 11818767
Drug: Mu-opioid receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mu-opioid receptor blockade (naloxone)
Trial: 7655204
Drug: Mepivacaine 2%
RxNorm normalized name: mepivacaine 2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepivacaine 2% (4 ml)
Trial: 7655204
Drug: Prilocaine 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prilocaine 2% (4 ml)
Trial: 7655204
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% (4 ml)
Trial: 2698273
Drug: Amineptine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amineptine 200 mg/day
Trial: 1099948
Drug: Inhaled isoproterenol
RxNorm normalized name: isoproterenol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled isoproterenol hydrochloride
Trial: 26351969
Drug: Sertraline hydrochloride,
RxNorm normalized name: Sertraline Hydrochloride, 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline hydrochloride, 50 to 100 mg/d
Trial: 23432534
Drug: Netazepide (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netazepide (1, 5, 25, and 100 mg)
Trial: 23432534
Drug: Netazepide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netazepide (100 mg) twice daily for 13 doses
Trial: 11737510
Drug: CHX 0.12%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHX 0.12% + CPC 0.05% (Perio.Aid, new formulation)
Trial: 8989272
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg ALN daily
Trial: 8989272
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg ALN daily
Trial: 8989272
Drug: 5.0 mg
RxNorm normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg ALN daily
Trial: 8989272
Drug: ALN (1.0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALN (1.0, 2.5, or 5.0 mg)
Trial: 8500697
Drug: Oral meals
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral meals
Trial: 29775553
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBMT) administered in one upper quadrant (wavelength: 660 nm; Power: 100 mW; Power density: 100 mW/cm2; Energy density per application point = 2 J/cm2; Total dose = 52 J/cm2; Irradiation time: 26 × 20 sec)
Trial: 24517720
Drug: Intravaginal progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravaginal progesterone gel (Crinone 8% gel)
Trial: 24517720
Drug: Intravaginal progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravaginal progesterone plus oral 2 mg estradiol hemihydrate (E2)
Trial: 24517720
Drug: Intravaginal progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravaginal progesterone plus oral 6 mg estradiol hemihydrate (E2)
Trial: 11700410
Drug: Methylprednisolone (MP)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MP) 15 mg/kg
Trial: 11700410
Drug: Tirilazad mesylate
RxNorm normalized name: tirilazad mesylate
DrugBank: Tirilazad (DB13050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirilazad mesylate (TM) 10 mg/kg
Trial: 7697692
Drug: Insulin-glipizide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-glipizide (5 mg/d)
Trial: 7697692
Drug: Insulin-placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-placebo
Trial: 3316301
Drug: Tiapamil 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiapamil 300 to 600 mg bid
Trial: 3316301
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 25 to 50 mg bid
Trial: 29731633
Drug: Once-monthly paliperidone
RxNorm normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Once-monthly paliperidone palmitate initiated </=1 week after hospitalization
Trial: 29731633
Drug: Once-monthly paliperidone
RxNorm normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Once-monthly paliperidone palmitate initiated >1 week after hospitalization
Trial: 22997786
Drug: Moxibustion treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion treatment (suspended moxibustion applied to Yanglingquan for 15 min, massage device used on pain area, self-help or mutual-aid treatment)
Trial: 22997786
Drug: Plaster application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plaster application (Goupi Gao applied to local pain area, treatment once daily for 5 days)
Trial: 20129478
Drug: Proactive telephone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive telephone breastfeeding support (2 weeks of daily calls by nurses)
Trial: 8236580
Drug: Oxytocin injections
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin injections during the first and second postoperative day
Trial: 8236580
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections during the first and second postoperative day
Trial: 31153628
Drug: Transmuscular quadratus
RxNorm normalized name: Pisum quadratum whole
DrugBank: Pisum sativum whole (DB15545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transmuscular quadratus lumborum (TQL) block with ropivacaine 0.75%, 30 ml
Trial: 31153628
Drug: Saline 30
RxNorm normalized name: Simply Saline 30 MG/ML Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 30 ml (control)
Trial: 26759107
Drug: First line
RxNorm normalized name: ALCOHOL 0.75 mL in 1 mL TOPICAL CLOTH [First Line Alcohol Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First line treatment in therapy group
Trial: 24391801
Drug: ART with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ART with concurrent active TB
Trial: 24391801
Drug: ART without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ART without concurrent TB or other AIDS-defining disease
Trial: 10683436
Drug: Conjugated linoleic
RxNorm normalized name: CONJUGATED LINOLEIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated linoleic acid (CLA) 4.2 g/day for 3 months
Trial: 31718542
Drug: Multimodal training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal training programme (MTP) with Integrated Brief Systemic Therapy (IBST) approach
Trial: 22277987
Drug: Transdermal 17β‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17β‐estradiol plus cyclical micronized progesterone for 3 months
Trial: 20350191
Drug: MVA (ACAM3000)
RxNorm normalized name: MVA
DrugBank: Modified vaccinia ankara (DB15483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA (ACAM3000) administered intradermally at 1 x 10(7) TCID(50)
Trial: 20350191
Drug: MVA (ACAM3000)
RxNorm normalized name: MVA
DrugBank: Modified vaccinia ankara (DB15483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA (ACAM3000) administered intramuscularly or subcutaneously at 1 x 10(8) TCID(50)
Trial: 15945400
Drug: promethazine 25
RxNorm normalized name: promethazine 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: promethazine 25 mg
Trial: 15945400
Drug: promethazine 25
RxNorm normalized name: promethazine 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: promethazine 25 mg plus pseudoephedrine 60 mg
Trial: 15945400
Drug: promethazine 25
RxNorm normalized name: promethazine 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: promethazine 25 mg plus d‐amphetamine 10 mg
Trial: 12841887
Drug: Levormeloxifene (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levormeloxifene (four different doses) for 12 months
Trial: 12841887
Drug: Raloxifene (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (three different doses) for 24 months
Trial: 1745622
Drug: Acetaminophen 1000
RxNorm normalized name: acetaminophen 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1000 mg plus codeine phosphate 60 mg (APAPCOD)
Trial: 6285814
Drug: Ketoconazole after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole after fasting (200 mg)
Trial: 6285814
Drug: Ketoconazole with
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole with orange juice (300 ml) (brand 1)
Trial: 6285814
Drug: Miconazole after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miconazole after fasting (250 mg)
Trial: 24499492
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg NRL001
Trial: 24499492
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg NRL001
Trial: 24499492
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg NRL001
Trial: 24499492
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g suppository (NRL001)
Trial: 24499492
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g suppository (NRL001)
Trial: 24499492
Drug: NRL001 (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRL001 (up to 15 mg)
Trial: 21791543
Drug: Pharmacist-led intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led intervention to optimize pharmacological therapy
Trial: 19402341
Drug: Commercial tablets
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial tablets (COM) 150 mg
Trial: 19402341
Drug: Magistral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magistral suspension (MAG) 150 mg
Trial: 19402341
Drug: Magistral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magistral suspension (MAG)
Trial: 19402341
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (COM and MAG)
Trial: 11845943
Drug: adapalene gel
RxNorm normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: adapalene gel 0.1%
Trial: 11845943
Drug: tretinoin microsphere
RxNorm normalized name: tretinoin microsphere
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tretinoin microsphere gel 0.1%
Trial: 28196003
Drug: Bictegravir (BIC)
DrugBank: Bictegravir (DB11799)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bictegravir (BIC) 5 mg
Trial: 28196003
Drug: Bictegravir (BIC)
DrugBank: Bictegravir (DB11799)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bictegravir (BIC) 25 mg
Trial: 28196003
Drug: Bictegravir (BIC)
DrugBank: Bictegravir (DB11799)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bictegravir (BIC) 50 mg
Trial: 28196003
Drug: Bictegravir (BIC)
DrugBank: Bictegravir (DB11799)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bictegravir (BIC) 100 mg
Trial: 24617242
Drug: Routine drug
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine drug anesthesia (group A)
Trial: 17375114
Drug: Low-energy parenteral
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy parenteral nutrition without amino acids
Trial: 17375114
Drug: Low-energy parenteral
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy parenteral nutrition containing amino acids (two types)
Trial: 16533223
Drug: Maintenance narrow-band
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance narrow-band UVB therapy for 2 months
Trial: 16533223
Drug: Maintenance narrow-band
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance narrow-band UVB therapy for plaque-type psoriasis
Trial: 16533223
Drug: No maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No maintenance therapy for plaque-type psoriasis
Trial: 8880107
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol 100 micrograms b.d.
Trial: 8880107
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol 400 micrograms q.d.s.
Trial: 1325319
Drug: Placebo (saline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline, 150 mmol/l NaCl)
Trial: 29912429
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy at 6 L/min for 6-12 hours
Trial: 24799602
Drug: Low 25(OH)D
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low 25(OH)D levels (<32 ng/mL)
Trial: 16824243
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural infusion of 0.2% ropivacaine (group EPI, n = 21)
Trial: 16824243
Drug: Paravertebral infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paravertebral infusion of 0.2% ropivacaine (group PVB, n = 21)
Trial: 9191873
Drug: OK-432 (picibanil)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OK-432 (picibanil) administered ID twice weekly for 3 months at dosages ranging from 1 KE to 20 KE
Trial: 9191873
Drug: OK-432 (picibanil)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OK-432 (picibanil) administered ID twice weekly for 3 months
Trial: 7693476
Drug: Nutrizym GR
RxNorm normalized name: SALICYLIC ACID 20 mg in 1 mL TOPICAL LIQUID [NUTRIXYL ANTI-DANDRUFF]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrizym GR (standard preparation)
Trial: 26509361
Drug: Fentanyl sublingual
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl sublingual spray (median dose = 800 mcg)
Trial: 25370587
Drug: Intravenous alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alteplase (0.9 mg/kg) plus standard care
Trial: 21118175
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of bisoprolol and ivabradine (mean dose 10.7±3.1 mg/day)
Trial: 21118175
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of bisoprolol and ivabradine
Trial: 16603801
Drug: Cumulative sums
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative sums (cusums) method with hourly readings
Trial: 1442344
Drug: Steroid regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid regimen A (7 weeks duration)
Trial: 1442344
Drug: Steroid regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid regimen B (15 weeks duration)
Trial: 31874985
Drug: treatment cream
RxNorm normalized name: Acne Treatment Cream
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment cream
Trial: 31874985
Drug: control cream
RxNorm normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: control cream
Trial: 31874985
Drug: anticipatory treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anticipatory treatment cues
Trial: 26111957
Drug: palonosetron (0.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: palonosetron (0.25, 0.75, or 2.25 mg)
Trial: 26111957
Drug: moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moxifloxacin (400 mg)
Trial: 24621778
Drug: Sitagliptin in
RxNorm normalized name: Product containing sitagliptin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin in combination with CSII therapy
Trial: 24621778
Drug: CSII monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSII monotherapy
Trial: 20451686
Drug: P‐OM3 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P‐OM3 4 g/day
Trial: 19818685
Drug: Fluorouracil (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil (800 mg/m2 per day, days 1-5, every 4 weeks)
Trial: 19818685
Drug: Irinotecan plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan plus cisplatin (irinotecan 70 mg/m2 on days 1 and 15, cisplatin 80 mg/m2 on day 1, every 4 weeks)
Trial: 19818685
Drug: S-1 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 (40 mg/m2 twice a day, days 1-28, every 6 weeks)
Trial: 11697841
Drug: Docetaxel at
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel at 100 mg/m2 every three weeks (with a switch to 40 mg/m2 weekly in case of severe toxicity)
Trial: 9596428
Drug: oxymetazoline nasal
RxNorm normalized name: oxymetazoline nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxymetazoline nasal spray (0.05%)
Trial: 9596428
Drug: double placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: double placebo (capsule and nasal spray)
Trial: 7869015
Drug: Monospecific antivenin
RxNorm normalized name: ANTIVENIN,CROTALIDAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monospecific antivenin therapy (60 ml administered intravenously at 6-hour intervals until blood coagulability is restored)
Trial: 7869015
Drug: Monospecific antivenin
RxNorm normalized name: ANTIVENIN,CROTALIDAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monospecific antivenin therapy
Trial: 3215145
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose T3 administration (25 micrograms per day for 4 weeks)
Trial: 28796588
Drug: G-CHOP (Obinutuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CHOP (Obinutuzumab plus CHOP)
Trial: 24951296
Drug: Nitrate-rich beetroot
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate-rich beetroot juice (70 mL) consumed 150 min before the first time trial
Trial: 24951296
Drug: Nitrate-rich beetroot
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate-rich beetroot juice (70 mL) consumed 75 min before the first time trial
Trial: 24951296
Drug: Nitrate-rich beetroot
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate-rich beetroot juice (35 mL top-up dose) after the first time trial
Trial: 19744307
Drug: Endocrine and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine and cytotoxic therapies
Trial: 16244017
Drug: Intraoperative IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative IV ondansetron (4 mg) followed by postoperative ondansetron (8 mg BID for up to 72 h)
Trial: 12107603
Drug: Digitoxin (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digitoxin (0.6 mg day 1, 0.4 mg day 2, then 0.1 mg daily)
Trial: 27741367
Drug: Investigational cigarette
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational cigarette with 0.4 mg/g nicotine content
Trial: 24113764
Drug: Transdiagnostic Internet‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdiagnostic Internet‐based maintenance treatment (TIMT)
Trial: 21835552
Drug: Post-discharge behavioral
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-discharge behavioral treatment
Trial: 11252284
Drug: Attitudes and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attitudes and behaviors associated with alcohol and drug problems like stimulus seeking, rule violations and bad judgement
Trial: 8109762
Drug: Intrathecal 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 2.5 mg bupivacaine + 22.2 +/- 4.6 mL epidural lidocaine
Trial: 8109762
Drug: Intrathecal 5
RxNorm normalized name: ZICONOTIDE 100MCG/ML INJ INTRATHECAL 5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 5 mg bupivacaine + 10.1 +/- 2.0 mL epidural lidocaine
Trial: 8109762
Drug: Intrathecal 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 7.5 mg bupivacaine
Trial: 8109762
Drug: Intrathecal 10
RxNorm normalized name: LIORESAL INTRATHECAL 10 MG in 20 ML (500 MCG/ML) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 10 mg bupivacaine
Trial: 2842144
Drug: Flumazenil (0.001,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.001, 0.003, 0.007 or 0.014 mg kg-1)
Trial: 26261386
Drug: fluconazole 150
RxNorm normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fluconazole 150 mg 1x weekly